Impact of major bleeding and thrombosis on 180‐day survival in patients with severe COVID‐19 supported with veno‐venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. (7th October 2021)

• Record Type: Journal Article
• Authors: Arachchillage, Deepa J.; Rajakaruna, Indika; Scott, Ian; Gaspar, Mihaela; Odho, Zain; Banya, Winston; Vlachou, Aikaterini; Isgro, Graziella; Cagova, Lenka; Wade, Joshua; Fleming, Lucy; Laffan, Mike; Szydlo, Richard; Ledot, Stephane; Jooste, Rachel; Vuylsteke, Alain; Yusuff, Hakeem
• Is Part Of: British journal of haematology. Volume 196:Number 3(2022)
• Page Start: 566
• Page End: 576
• Publication Date: 2021-10-07
• Subjects: COVID‐19 -- extracorporeal membrane oxygenation -- bleeding -- thrombosis -- mortality; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17870
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Bleeding and thrombosis are major complications in patients supported with extracorporeal membrane oxygenation (ECMO). In this multicentre observational study of 152 consecutive patients (≥18 years) with severe COVID‐19 supported by veno‐venous (VV) ECMO in four UK commissioned centres during the first wave of the COVID‐19 pandemic (1 March to 31 May 2020), we assessed the incidence of major bleeding and thrombosis and their association with 180‐day mortality. Median age (range) was 47 years (23–65) and 75% were male. Overall, the 180‐day survival was 70·4% (107/152). The rate of major bleeding was 30·9% (47/152), of which intracranial bleeding (ICH) was 34% (16/47). There were 96 thrombotic events (63·1%) consisting of venous 44·7% [68/152 of which 66·2% were pulmonary embolism (PE)], arterial 18·6% (13/152) and ECMO circuit thrombosis 9·9% (15/152). In multivariate analysis, only raised lactate dehydrogenase (LDH) at the initiation of VV ECMO was associated with an increased risk of thrombosis [hazard ratio (HR) 1·92, 95% CI 1·21‐3·03]. Major bleeding and ICH were associated with 3·87‐fold (95% CI 2·10–7·23) and 5·97‐fold [95% confidence interval (CI) 2·36–15·04] increased risk of mortality and PE with a 2·00‐fold (95% CI1·09–3·56) risk of mortality. This highlights the difficult balancing act often encountered when managing coagulopathy in COVID‐19 patients supported with ECMO.